Biden’s decision is to transfer coronavirus shots and treatments to the commercial market after shouldering such costs since the beginning of the pandemic, La Opinion newspaper reported on Friday.
According to the White House Covid-19 Response Coordinator Dr. Ashish Jha, the Joe Biden administration is coming up with the idea how it will make the transition from the “acute emergency phase” of the pandemic, in which the Government paid most of Covid-19 tests, shots and treatments.
On August 30, the Department of Health and Human Services (HHS) will hold a meeting with representatives from pharmacy chains, state health departments and drug producers interested in a Covid-19 treatment industry, according to The Wall Street Journal.
An HHS spokesman estimated that commercialization process is expected to take months to finalize. Once anew, the big winners of such a decision would be the Pfizer, BioNtech and Moderna pharmaceutical companies, in charge of manufacturing major Covid-19 shots used in the United States.
Pfizer –with its Covid-19 Paxlovid- alone reported a revenue of $8.1 billion in 2Q 2022, a drug used to treat President Joe Biden.
Both administrations, former President Donald Trump (2017-2021) and Joe Biden´s have always planned to transfer Covid-19 shot costs and treatments from government to people, a pathway that is already beginning.